HIMSHims & Hers Health, Inc. — stock analysis & sentiment

At $27.44, the stock sits closer to the bottom of its 52-week range than the top, with a low of $13.74 and a high of $65.30 behind it. That span — the high is nearly five times the low — describes a stock that has traded across an unusually wide band over the past year, and the current price sits roughly in the lower-middle of it, well below the highs but at roughly double the lows.

The market values the business at about $6.4 billion. Revenue grew 38% over the trailing period, but the company is not currently profitable, carrying a profit margin of about -5.5%, so the market is pricing it on expected future earnings rather than current ones: a forward price-to-earnings ratio near 33 and a price-to-book multiple close to 19.6 both reflect a valuation set against growth that has not yet translated into positive net income. A beta of 2.41 means the shares have historically moved more than twice as much as the broader market in both directions, which is consistent with the width of the 52-week range.

The recent news flow is dominated by one theme and it is company-specific rather than sector-wide: a securities fraud class action. Multiple law firms — including Glancy Prongay, Kahn Swick & Foti, Bronstein Gewirtz & Grossman, Rosen, Kaplan Fox, and Kessler Topaz — issued investor notices between September 4 and September 9, 2026, referencing filing deadlines and allegations tied to privacy and billing practices and a stock decline of more than 14%. Aside from one item noting the stock gained on a down day for the market, and one unrelated notice concerning a different company, there is little in the current news set about operations, products, or the wider healthcare sector.